Amundi Boosts Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Amundi boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 30.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 70,266 shares of the medical research company's stock after buying an additional 16,599 shares during the quarter. Amundi owned approximately 0.14% of Charles River Laboratories International worth $13,204,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. PNC Financial Services Group Inc. lifted its stake in Charles River Laboratories International by 25.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 14,278 shares of the medical research company's stock valued at $2,636,000 after acquiring an additional 2,916 shares in the last quarter. Edgestream Partners L.P. purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at $2,378,000. E Fund Management Co. Ltd. purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at $336,000. Raymond James Financial Inc. purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at $42,776,000. Finally, Arizona State Retirement System increased its position in shares of Charles River Laboratories International by 1.6% during the 4th quarter. Arizona State Retirement System now owns 14,995 shares of the medical research company's stock valued at $2,768,000 after purchasing an additional 237 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Price Performance

Shares of CRL traded up $2.01 during trading hours on Tuesday, reaching $177.02. 1,011,890 shares of the company's stock traded hands, compared to its average volume of 711,526. The stock has a market cap of $9.05 billion, a PE ratio of 1,180.13, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm's 50 day simple moving average is $167.46 and its 200-day simple moving average is $184.33. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $274.77.

Remove Ads

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International's quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.46 EPS. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James C. Foster bought 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

CRL has been the subject of several research analyst reports. Robert W. Baird decreased their target price on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. The Goldman Sachs Group decreased their target price on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. UBS Group reaffirmed a "neutral" rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Finally, Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and an average price target of $198.36.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).